Introduction {#s1}
============

Systemic lupus erythematosus (SLE) is an autoimmune disorder characterised by T and B cell dysfunction, autoantibody production and end organ damage, with 30% of deaths due to premature cardiovascular disease (CVD). Multiple studies demonstrate accelerated atherosclerosis in SLE patients, with risk of developing atherosclerosis increased, on average, 2-to 10-fold compared with healthy controls.[@R1] Although aetiology of SLE-accelerated atherosclerosis remains unknown, studies in patients and animal models implicate some likely suspects including the CD40--CD40L signalling pathway,[@R2] [@R4] decreased TGF-β,[@R8] decreased regulatory T cells (T~reg~),[@R9] increased proportions and activation of T~h1~ and T~h17~ cells[@R10] [@R13] and production of autoantibodies against β2GPI--oxLDL complexes.[@R16]

T cell populations including T~h1~ and T~h17~ cells can be pro-atherogenic,[@R9] [@R13] [@R17] while T~reg~ have been shown to be atheroprotective, likely through production of anti-inflammatory cytokines including interleukin (IL)-10.[@R11] [@R20] It is well established that, in both mice and humans, SLE T cells are hyperactivated and produce increased amounts of IFNγ and IL-17, inflammatory cytokines associated with T~h1~ and T~h17~ cells, respectively.[@R10] [@R24] The B6.Sle1.2.3 (B6.SLE) mouse model contains three genetic loci (Sle1, Sle2 and Sle3) which confer SLE susceptibility.[@R27] When all three loci are present, mice display a fully penetrant lupus phenotype that develops with age and is similar to the human disease.[@R27] [@R28] One aspect of this phenotype is T cell activation. Using a bone marrow transplant model, our laboratory has demonstrated that LDLr^−/−^ mice receiving SLE bone marrow (LDLr.SLE) have increased atherosclerosis compared with mice receiving B6 bone marrow (LDLr.B6 controls).[@R24] [@R29] This increased atherosclerosis was accompanied by an increase in the proportion of T cells within the atherosclerotic lesions, raising the question of whether SLE T cells are important for acceleration of lesion progression. Although, due to their role in autoantibody production, B cells are the focus of the majority of clinical trials of new SLE therapies, T cells also play a significant role in disease progression. Given the role of T cells in atherosclerosis, they may be an important target to consider when developing therapies to treat SLE and CVD. In the current study, we focus on the role of SLE CD4^+^ T cells in accelerated atherosclerosis.

Methods {#s2}
=======

Mice {#s2a}
----

C57BL/6J mice (B6), B6.129S7*-Rag1*^tm1Mom^/J (Rag^−/−^), B6;129S7-*Ldlr^tm1Her^*/J (LDLr^−/−^) and B6.Cg-*Foxp3^tm2(EGFP)Tch^*/J mice were originally obtained from The Jackson Laboratory. Rag^−/−^ and LDLr^−/−^ mice were crossed to obtain LDLr^−/−^, Rag^−/−^ mice. The congenic strain B6.*Sle1.2.3* (B6.SLE), originally obtained from Edward K Wakeland UTSW, Dallas, Texas, USA, has been described.[@R24] [@R27] [@R28] B6.Cg-*Foxp3^tm2(EGFP)Tch^*/J mice were crossed with the B6.SLE strain to obtain B6.SLE mice with FoxP3-driven GFP expression (B6.SLE^FoxP3−GFP^). All mice are on the C57BL/6 background and maintained in our colony. Female mice were used for all studies. All procedures were approved by the Vanderbilt Institutional Animal Care and Use Committee.

Statistical analyses {#s2b}
--------------------

Statistical significance between two groups was calculated using a Student t test. Differences among three or more variables were calculated using a one-way analysis of variance (ANOVA) with a Bonferroni post-test. A p value of \<0.05 was considered statistically significant. All calculations were performed and graphs generated using GraphPad Prism Software (Graph Pad Software, Inc, La Jolla, California, USA). More detailed methods can be found in the online supplementary material.

Results {#s3}
=======

B6.SLE CD4^+^ T cells are sufficient to induce SLE-accelerated atherosclerosis {#s3a}
------------------------------------------------------------------------------

An increased prevalence of atherosclerosis has been associated with SLE in both humans and mouse models.[@R1] [@R24] [@R29] To date, it is not clear whether one specific cell type is responsible for accelerated atherosclerosis in SLE. Results from our previous studies indicated that, along with larger atherosclerotic lesions, more CD4^+^ T cells were present in the lesions of LDLr.SLE mice.[@R24] [@R29] [@R33] This suggests a role for CD4^+^ T cells in SLE-accelerated atherosclerosis. Therefore, we hypothesised that B6.SLE CD4^+^ T cells were sufficient to accelerate atherosclerosis. To test this hypothesis, we isolated CD4^+^ T cells (\>90% purity) from 6-month-old B6 and B6.SLE mice and adoptively transferred them to LDLr^−/−^, Rag^−/−^ mice, an atherosclerotic mouse model lacking functional B and T cells. Two weeks following transfer, all animals were placed on a Western diet for 10 additional weeks (see study design, [figure 1](#ANNRHEUMDIS2013203759F1){ref-type="fig"}A). B6.SLE donors had active lupus, confirmed by the presence of dsDNA autoantibody titres ([figure 1](#ANNRHEUMDIS2013203759F1){ref-type="fig"}B). At sacrifice, however, there were no differences between recipient mice for dsDNA autoantibody titres indicating that there was no significant transfer of B cells or autoantibody production in the recipient animals ([figure 1](#ANNRHEUMDIS2013203759F1){ref-type="fig"}B). Additionally, there was no difference in total spleen cell number, body weight, spleen to body weight ratio or urine protein grade ([figure 1](#ANNRHEUMDIS2013203759F1){ref-type="fig"}C and see online supplementary figure S1A, B and E). Numbers of CD4^+^ T cells recovered from spleens were similar between B6 and B6.SLE recipients ([figure 1](#ANNRHEUMDIS2013203759F1){ref-type="fig"}D). Excitingly, atherosclerotic lesion area in the aortic root was increased 36% in mice receiving B6.SLE CD4^+^ T cells ([figure 1](#ANNRHEUMDIS2013203759F1){ref-type="fig"}E). This increase in atherosclerosis was independent of serum cholesterol and triglyceride levels (see online supplementary figure S1C,D), supporting a specific role of CD4^+^ T cells in lupus-accelerated atherosclerosis. Collectively, these data demonstrate that the CD4^+^ T cells from B6.SLE mice are sufficient to accelerate atherosclerosis when transferred to a non-lupus, atherosclerosis-susceptible mouse.

![B6.SLE CD4^+^ T cells are sufficient to accelerate atherosclerosis. (A) Study design. (B) dsDNA titres from donor mice (pretransfer) and recipient mice at the time of sacrifice. (C) Total number of cells in the spleens of recipient mice. (D) The total number of CD4 T cells recovered from the spleens of recipient mice. (E) Representative images of Oil Red O stained sections of the aortic root (left) and quantification of the total lesion area based on the Oil Red O staining (right). Data are representative of n=7--15 mice per group. \*\*\*Significant at p\<0.001. SLE, systemic lupus erythematosus.](annrheumdis-2013-203759f01){#ANNRHEUMDIS2013203759F1}

B6.SLE T~reg~ have altered function and phenotype {#s3b}
-------------------------------------------------

T~reg~ dysfunction or reduced numbers of T~reg~ may contribute to the inflammatory capabilities of B6.SLE CD4^+^ T cells (see online supplementary figure S2 and ref 28). Data from human and mouse studies are unclear as to whether T~reg~ are proportionally or functionally different in SLE patients versus healthy subjects.[@R34] Although there are a number of effector T cells (T~eff~) and T~reg~ markers, here we define T~eff~ as CD4^+^FoxP3^−^ and T~reg~ as positive for both CD4 and FoxP3. Examination of donor T~reg~ showed a twofold increase in the proportion of CD4^+^FoxP3^+^ T~reg~ in B6.SLE compared with B6 mice ([figure 2](#ANNRHEUMDIS2013203759F2){ref-type="fig"}A).

![An increased proportion of B6.SLE T~eff~ and T~reg~ are IL-17^+^. (A) Dot plots of FoxP3 versus CD4 (gated on CD4^+^ cells), left panel and the resulting quantification of CD4^+^FoxP3^+^ cells, right panel. Whole splenocytes were cultured with or without anti-CD3/CD28 stimulation for 5 h and then subjected to intracellular staining for IL-17 (B) and IL-10 (C). The percentage of cytokine positive cells was measured by flow cytometry. (B) The percent of IL-17^+^ cells in the CD4^+^FoxP3^−^ (left) and CD4^+^FoxP3^+^ (right) populations. (C) The percent of IL-10^+^ cells in the CD4^+^FoxP3^−^ (left) and CD4^+^FoxP3^+^ (right) populations. Data are representative of n=4--6, 6-month-old mice per group. \*^,^ \*\* and \*\*\* indicate significance at p\<0.05, 0.01 and 0.001, respectively. SLE, systemic lupus erythematosus.](annrheumdis-2013-203759f02){#ANNRHEUMDIS2013203759F2}

First, given the dysregulation of cytokine production by CD4^+^ T cells in the B6.SLE model (see online supplementary figure S2D--F), and to determine whether SLE T~reg~ possessed qualitative differences in cytokine production compared with their B6 counterparts, we examined cytokine secretion by CD4^+^FoxP3^−^ T~eff~ and CD4^+^FoxP3^+^ T~reg~ after phorbol 12-myristate 13-acetate (PMA) and ionomycin stimulation of whole splenocytes. Not unexpectedly, B6.SLE CD4^+^FoxP3^−^ cells exhibited a 3.6-fold increase in the proportion of IL-17-producing cells compared with B6 mice ([figure 2](#ANNRHEUMDIS2013203759F2){ref-type="fig"}B, left panel). Surprisingly, however, B6.SLE CD4^+^FoxP3^+^ T~reg~ also exhibited a large increase in the percentage of IL-17^+^ cells ([figure 2](#ANNRHEUMDIS2013203759F2){ref-type="fig"}B, right panel). Greater than 6% of T~reg~ produced IL-17; a twofold increase over unstimulated B6.SLE CD4^+^FoxP3^−^ T~eff~. This percentage was further increased upon stimulation, with greater than 12% of T~reg~ secreting IL-17. These data suggest dysregulation of IL-17 production by CD4^+^FoxP3^+^ T~reg~ in B6.SLE mice.

T~reg~ exert their anti-inflammatory effects in part through IL-10.[@R38] IL-10 is classically anti-inflammatory but is associated with SLE disease activity.[@R39] CD4^+^FoxP3^−^ T cells in B6 and B6.SLE mice did not differ in terms of the proportion of IL-10^+^ cells at baseline. However, after stimulation, B6.SLE CD4^+^FoxP3^−^ cells had a twofold increase in IL-10^+^ cells compared with B6 ([figure 2](#ANNRHEUMDIS2013203759F2){ref-type="fig"}C, left panel), as would be expected in a model of SLE. Although both B6 and B6.SLE T~reg~ responded to stimulation by increasing the proportion of cells expressing IL-10, there was no significant difference between strains of mice ([figure 2](#ANNRHEUMDIS2013203759F2){ref-type="fig"}C, right panel).

B6.SLE T~reg~ have reduced levels of IL-10R expression {#s3c}
------------------------------------------------------

A recent report indicated that T~reg~ IL-10 receptor (IL-10R) expression facilitates suppression of T~h17~ responses.[@R40] Because we observed increased IL-17 production by T~reg~ ([figure 2](#ANNRHEUMDIS2013203759F2){ref-type="fig"}B) but also increased production of IL-10 in B6.SLE mice ([figure 2](#ANNRHEUMDIS2013203759F2){ref-type="fig"}C and see online supplementary figure S2F), we hypothesised that IL-10R expression might be reduced in B6.SLE. The proportion of CD4^+^FoxP3^−^IL-10R^+^ cells was similar between B6 and B6.SLE ([figure 3](#ANNRHEUMDIS2013203759F3){ref-type="fig"}A,B). However, there was a 1.5-fold reduction of IL-10R^+^ cells in the B6.SLE T~reg~ compartment compared with B6. Expression levels as measured by mean fluorescence intensity (MFI) were not different between B6 and B6.SLE ([figure 3](#ANNRHEUMDIS2013203759F3){ref-type="fig"}C).

![Reduced IL-10 receptor expression in B6.SLE T~reg~ and T~eff~ populations. Whole splenocytes were obtained from 6-month-old mice and examined for surface expression of the IL-10R by flow cytometry. Samples were gated on CD4^+^ cells, and then the cell populations of interest were examined. (A) Contour plots showing IL-10R expression on CD4^+^FoxP3^−^ (left) and CD4^+^FoxP3^+^ (right) cells from B6 (top) and B6.SLE (bottom) mice. (B) Quantification showing the proportion of each cell population expressing IL-10R. (C) Quantification of the mean fluorescence intensity of IL-10R staining on T~reg~ and T~eff~ populations. Data are representative of at least six mice per group. \* Indicates significance at p\<0.05. SLE, systemic lupus erythematosus.](annrheumdis-2013-203759f03){#ANNRHEUMDIS2013203759F3}

B6.SLE T~eff~ are resistant to T~reg~-mediated suppression {#s3d}
----------------------------------------------------------

Despite the increased proportion of T~reg~, T~eff~ activation persists (see online supplementary figure S2). This, in addition to increased IL-17 production and reduced IL-10R expression by B6.SLE T~reg~, led us to hypothesise that these cells are dysfunctional in their ability to suppress T~eff~. To test this hypothesis, we isolated T~reg~ and T~eff~ and performed in vitro functional assays. Because FoxP3 is an intracellular marker, we isolated these cells based on CD25 expression. CD4^+^CD25^+^ cells served as T~reg~ in this assay while T~eff~ were defined as CD4^+^CD25^−^. Suppressive function was determined as the ability of T~reg~ to suppress proliferation of T~eff~. When challenged with strain-matched T~eff~, B6.SLE T~reg~ were less suppressive compared with B6 T~reg~ ([figure 4](#ANNRHEUMDIS2013203759F4){ref-type="fig"}A,B). Surprisingly, when challenged with B6 T~eff~, B6.SLE T~reg~ were as suppressive as B6 T~reg~, suggesting that B6.SLE T~eff~ are resistant to suppression. To further confirm this, we incubated both B6 and B6.SLE T~reg~ with B6.SLE T~eff~. The ability of T~reg~ from both strains to suppress B6.SLE T~eff~ proliferation was reduced ([figure 4](#ANNRHEUMDIS2013203759F4){ref-type="fig"}A,B) compared with their inhibition of B6 T~eff~. These data suggest that, similar to results seen in some SLE patients,[@R37] [@R41] [@R42] B6.SLE T~eff~ are resistant to T~reg~-mediated suppression.

![B6.SLE Teff are resistant to T~reg~-mediated suppression. Suppression assays were performed from purified CD4^+^CD25^+^ (T~reg~) and CD4^+^CD25 ^−^ (T~eff~) cells. (A) Percent inhibition of proliferation by B6 and B6.SLE T~reg~ challenged with B6 or B6.SLE T~eff~. (B) Comparison of inhibition at the 1:4 ratio of T~reg~ to T~eff~. (C) All samples were gated based on CD4^+^ T cells, and then the individual cell populations of interest were examined. Representative histograms of GITR expression (top panel) on CD4^+^ cell populations in B6 (red line) and B6.SLE (blue line) mice; quantification of GITR expression based on mean fluorescence intensity (top right panel); representative histograms of inducible costimulatory molecule (ICOS) expression (bottom panel) on CD4^+^ cell populations in B6 (red line) and B6.SLE (blue line) mice; Quantification of ICOS expression based on mean fluorescence intensity (bottom right panel). Data reflect n=6--8 mice per group from one of two representative experiments. \*^,^ \*\* and \*\*\* indicate significance at p\<0.05, 0.01 and 0.001, respectively. GITR, glucocorticoid-induced TNFR-related protein; SLE, systemic lupus erythematosus.](annrheumdis-2013-203759f04){#ANNRHEUMDIS2013203759F4}

We next measured surface expression of glucocorticoid-induced TNFR-related protein (GITR), a surface receptor upregulated on newly activated T cells. Surface expression of GITR on T~eff~ is thought to extend survival and confer resistance to suppression by T~reg~.[@R43] Supporting the functional assay, B6.SLE CD4^+^ T cell populations exhibited a twofold increase in GITR expression compared with B6 ([figure 4](#ANNRHEUMDIS2013203759F4){ref-type="fig"}C, top panel). Surface expression of inducible costimulatory molecule (ICOS), typically upregulated on the surface of activated T cells and important in Th2 responses,[@R44] was increased twofold on B6.SLE CD4^+^ T cells compared with B6 ([figure 4](#ANNRHEUMDIS2013203759F4){ref-type="fig"}C, bottom panel). There were no differences between T~eff~ or T~reg~ cell populations. These data support results from [figure 4](#ANNRHEUMDIS2013203759F4){ref-type="fig"}A and online supplementary figure S1 indicating T cell activation and resistance of T~eff~ to T~reg~-mediated suppression in the B6.SLE model.

B6 T~reg~ are not sufficient to prevent B6.SLE T~eff~-mediated acceleration of atherosclerosis {#s3e}
----------------------------------------------------------------------------------------------

Data thus far support the hypothesis that T~eff~ resistance to T~reg~-mediated suppression in B6.SLE mice may accelerate atherosclerosis. To test this hypothesis, we performed a T cell transfer study in which CD4^+^FoxP3^−^ T~eff~ were isolated from 6-month-old B6^FoxP3−GFP^ and B6.SLE^FoxP3−GFP^ mice while CD4^+^FoxP3^+^ T~reg~ were isolated from B6^FoxP3−GFP^ mice. A control group of LDLr^−/−^, Rag^−/−^ mice received both CD4^+^FoxP3^+^ T~reg~ and CD4^+^FoxP3^−^ T~eff~ from B6^FoxP3−GFP^ mice (B6 TE:B6 TR) while the experimental group received B6.SLE^FoxP3−GFP^ T~eff~ with B6^FoxP3−GFP^ T~reg~ (B6.SLE TE:B6 TR). The study followed the timeline as shown in [figure 1](#ANNRHEUMDIS2013203759F1){ref-type="fig"}A. As in our previous transfer experiment, we noted no differences in body weight, spleen to body weight ratio, total number of splenocytes or in the total number of CD4^+^ T cells in the spleens at sacrifice (see online supplementary figure S3A--D). Furthermore, there were no differences in urine protein grade, as all recipients had little to no urine protein (see online supplementary figure S3E). Upon examination of the aortic root, the total lesion area was increased 44% in the B6.SLE TE:B6 TR experimental group compared with the B6 TE:B6 TR mice ([figure 5](#ANNRHEUMDIS2013203759F5){ref-type="fig"}A). In addition, the percentage of CD4^+^ T cells in the lesions was slightly, but significantly, higher in the B6.SLE T~eff~ recipients compared with control ([figure 5](#ANNRHEUMDIS2013203759F5){ref-type="fig"}B). When examining the T cell populations within the spleens of recipients, we discovered that, despite the presence of B6 T~reg~, there was a greater than twofold increase in the percentage of T~eff~ in the SLE TE:B6 TR group which were producing IL-17 ([figure 5](#ANNRHEUMDIS2013203759F5){ref-type="fig"}C, left panel). Interestingly, in recipients of SLE TE:B6 TR, there was a 2.8-fold increase in the percentage of T~reg~ which were producing IL-17 ([figure 5](#ANNRHEUMDIS2013203759F5){ref-type="fig"}C, right panel). Accompanying this increase in the proportion of IL-17^+^ cells was a significant reduction in the percentage of IL-10R^+^ cells in the SLE TE:B6 TR group in both T~reg~ and T~eff~ ([figure 5](#ANNRHEUMDIS2013203759F5){ref-type="fig"}D). These data implicate B6.SLE T~eff~ as the primary player in SLE-accelerated atherosclerosis, and suggest T~eff~-mediated dysregulation of T~reg~ IL-17 production and IL-10R expression as a potential mechanism by which T~eff~ cause this acceleration.

![B6.SLE T~eff~ accelerate atherosclerosis independent of the source of T~reg~. (A) Representative images of Oil Red O stained sections of the aortic root (top) and quantification of the total lesion area based on the Oil Red O staining (bottom). (B) Representative images of immunofluorescent staining for CD4 ^+^ cells (red), with 4′, 6-diamidino-2-phenylindole (DAPI) staining (blue) for nuclei (top) and quantification of the proportion of total cells that were shown to express CD4 (bottom). (C) Whole splenocytes from recipients were cultured with or without anti-CD3/CD28 stimulation for 5 h and then subjected to intracellular staining for IL-17. The percentage of cytokine positive cells was measured by flow cytometry. The percent of IL-17^+^ cells in the CD4^+^FoxP3^−^ (left) and CD4^+^FoxP3^+^ (right) populations. (D) IL-10R expression was measured on T~eff~ and T~reg~ from recipients. Cells were gated based on CD4^+^ expression, then separated into T~eff~ and T~reg~ populations. IL-10R staining was measured by flow cytometry. Data reflect n=6 mice per group. \*^,^ \*\* and \*\*\* indicate significance at p\<0.05, 0.01 and 0.001, respectively. SLE, systemic lupus erythematosus.](annrheumdis-2013-203759f05){#ANNRHEUMDIS2013203759F5}

Discussion {#s4}
==========

SLE and atherosclerosis are complex chronic inflammatory diseases characterised by immune dysfunction. Evidence supports interplay between the two diseases, with studies showing accelerated atherosclerosis in SLE. Increased activation of T cells has been demonstrated in both SLE patients and in mouse models of SLE including (NZB×NZW)F1,[@R45] MRL/MpJ-Fas(lpr/lpr)/J[@R46] and B6.SLE mice.[@R24] [@R27] [@R28] Given the important effector and regulatory functions of T cells in atherosclerosis and that accelerated CVD is a major cause of death for SLE patients, it has been suggested that T cells may be important to consider when developing therapies for SLE and SLE-accelerated atherosclerosis (reviewed in[@R47]). However, most clinical studies to date have focused on B cells due to their role in producing the autoantibodies that lead to immune complex formation and the resultant end organ damage in SLE. The current study was undertaken to determine the effects of B6.SLE CD4^+^ T cells on atherosclerosis. While mice are not optimal for study of plaque vulnerability and rupture, common properties of atherosclerotic lesions in SLE patients, they provide a platform to study the complicated mechanisms by which the immune system contributes to plaque development. We chose the LDLr^−/−^, Rag^−/−^ model, allowing us to determine the direct effects of CD4^+^ T cells on atherosclerosis, independent of other SLE immune cell populations including the autoantibody-producing B cells. Importantly, at the time of sacrifice, T cell recipients did not have an SLE phenotype, attributing any effects on atherosclerosis to the T cells. Here, we demonstrate a direct role for B6.SLE CD4^+^ T cells in accelerated atherosclerosis.

While T~eff~ including T~h1~ cells are generally thought to be atherogenic[@R48] [@R49] (and reviewed in[@R50]), T~reg~ have been shown to have antiatherogenic properties. Ait-Oufella *et al*[@R11] showed a negative correlation between T~reg~ number and atherosclerosis development (reviewed in[@R51]), and it has been directly demonstrated that depletion of T~reg~ results in increased atherosclerosis.[@R52] In our study, B6.SLE mice had an increased proportion of CD4^+^FoxP3^+^ T~reg~, yet atherosclerosis was increased with CD4^+^ T cell transfer from these mice. T~reg~ and T~h17~ dysregulation is a common feature in SLE. We made the unexpected observation that an increased proportion of B6.SLE T~reg~ was secreting IL-17, a cytokine typically attributed to T~h17~ cells. IL-17 contributes to tissue damage in SLE and is correlated with disease activity.[@R53] [@R54] Interestingly, the proportion of these cells making IL-17 was higher than that of T~eff~, suggesting that T~reg~ are a part of the IL-17 dysregulation observed in SLE and have the potential to contribute to tissue damage. IL-17 is also believed to play a role in atherosclerosis, although whether it contributes to or reduces atherosclerosis is unclear due to the existence of studies supporting both possibilities.[@R13] [@R19] [@R55] Since IL-17-producing cells likely play a role in atherosclerosis, the fact that significant proportions of B6.SLE T~reg~ secrete IL-17 identifies them as potential contributors to SLE-accelerated atherosclerosis. A report by Chaudhry *et al*[@R40] concluded that T~reg~ IL-10R expression is required to suppress inflammation mediated by T~h17~ cells. This led us to ask the question as to whether IL-10R expression was reduced in B6.SLE T cell populations. Reduced IL-10R expression could explain the persistence of inflammation despite increased IL-10 in the context of SLE and why an increase of this antiatherogenic cytokine does not lead to reduced atherosclerosis. Indeed, the proportion of IL-10R^+^ cells in the T~reg~ populations from B6.SLE mice was reduced. These data led us to hypothesise that B6.SLE T~reg~ have reduced suppressive capacity. On the contrary, results from T~reg~ functional assays demonstrated intact suppressive function of B6.SLE CD4^+^CD25^+^ T~reg~ but that B6.SLE T~eff~ are resistant to T~reg~-mediated suppression. These data are comparable with some studies in SLE patients which point to T~eff~ resistance rather than T~reg~ dysfunction.[@R37] [@R56]

Given the damaging effects of IL-17 in SLE, uncovering the underlying mechanisms behind the dysregulation in IL-17 and IL-10R may be important for our understanding of the interplay between SLE and atherosclerosis. Indeed, a recent study in SLE patients with atherosclerosis has shed light on a potential atherosclerotic role for IL-17 in SLE by demonstrating that these patients have increased serum levels of IL-17 compared with SLE patients and healthy controls without atherosclerosis.[@R57] Importantly, results from our study implicate B6.SLE T~eff~ as being responsible for this dysregulation of T~reg~ IL-17 production and IL-10R expression. With transfer of B6.SLE T~eff~ and B6 T~reg~, atherosclerosis was increased. This increase, despite the presence of wild-type T~reg~, indicates that T~eff~ resistance to T~reg~-mediated suppression may be a strong contributing factor in this mechanism. Not only did B6 T~reg~ fail to suppress B6.SLE T~eff~-accelerated atherosclerosis, their phenotype appeared to be altered by the presence of B6.SLE T~eff~, resulting in an increased proportion of B6 T~reg~ producing IL-17 and a reduced percentage of cells expressing IL-10R. This suggests that B6.SLE T~eff~ resistance may be a direct result of their ability to alter IL-10R expression and, subsequently, IL-17 production by T~reg~. One limitation of this study, however, is our ability to definitively know whether the altered T~reg~ phenotype in SLE TE:B6 TR recipients was due to changes in the original B6 T~reg~ or conversion of B6.SLE T~eff~ to T~reg~ with a dysfunctional phenotype. We are currently developing the reporter mice which would allow us to map T~reg~ that become ex-T~reg~[@R58] and these studies are the focus of future experiments.

With evidence mounting for the antiatherogenic role of T~reg~, increased focus has been placed on these cells as a therapeutic target for atherosclerosis. Recent studies have identified a number of potential mechanisms involved in T~reg~ suppression that may prove useful for enhancement of suppression and/or T~reg~ numbers including MYD88 signalling in dendritic cells,[@R20] the IL-33--ST2 interaction,[@R59] CD39 and CD73 signalling, CTLA-4 and LAG-3.[@R60] However, data from the current study favour T~eff~ resistance over T~reg~-mediated suppression as a major culprit in SLE and suggest that, at least in the context of SLE and atherosclerosis, targeting mechanisms of T~eff~ resistance may prove most effective. Given our data, we postulate that therapies targeting IL-17 production, and perhaps IL-10R expression, would prove effective in treatment of SLE-accelerated atherosclerosis.

Multiple aspects of T cell dysregulation in B6.SLE mice suggest these cells have the potential to accelerate atherosclerosis. To date, speculation regarding their role in SLE-accelerated atherosclerosis has far outweighed any direct evidence supporting this hypothesis. In the current study, we demonstrate (1) B6.SLE CD4^+^ T cells are sufficient to accelerate atherosclerosis, (2) B6.SLE T~eff~ are resistant to T~reg~-mediated suppression, (3) dysregulation of IL-17 production by T~reg~, with a possible role for the IL-10R in this process and (4) B6.SLE T~eff~ are likely the primary T cell type involved in the observed accelerated atherosclerosis, potentially through their ability to alter T~reg~ IL-17 production and IL-10R expression. These data provide strong evidence for a causal role of CD4^+^ T cells and, specifically, for B6.SLE T~eff~, in SLE-accelerated atherosclerosis. To our knowledge, this is the first study to provide such evidence. These results emphasise the importance of considering T cell-targeted therapies when developing strategies to treat SLE and SLE-accelerated atherosclerosis and suggest that, in SLE, T~eff~ may be a more desirable target for therapy than T~reg~.
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